Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026, and August 4, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.
Chemours Case Details
The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:
- Defendants had materially overstated aftermarket demand for their Opteon products;
- demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year;
- as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and
- as a result, Defendants’ public statements were materially false and misleading at all relevant times.
What’s Next for Chemours Investors?
A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
CC — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”